Physician profile
Audrey Buxbaum
NPI 1265530679
$2,444.68
in general payments reported to CMS, 2019-2025
23 companies · $735 in 2025
The $735 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $15.00 · 2021: $200 · 2022: $218 · 2023: $234 · 2024: $571 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $498.95 | 2023-2025 | Veozah |
| Organon LLC | $326.60 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $259.95 | 2021-2025 | |
| Millicent US INC | $176.47 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Avion Pharmaceuticals | $151.42 | 2019-2021 | |
| Abbvie INC. | $129.19 | 2019-2023 | Lo Loestrin Fe |
| Evofem Biosciences, INC. | $129.09 | 2021-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $116.72 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $112.69 | 2022-2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $110.95 | 2019-2025 | Gardasil 9, Gardasil |
| Hologic Sales and Service, LLC | $106.83 | 2023-2025 | Aptima |
| Allergan, INC. | $43.61 | 2019 | |
| Sumitomo Pharma America, INC. | $41.41 | 2024 | Myfembree |
| Amag Pharmaceuticals, INC. | $39.10 | 2019 | |
| Duchesnay USA Incorporated | $37.68 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $35.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.67 | 2025 | |
| Therapeuticsmd, INC. | $21.24 | 2019 | |
| Pfizer INC. | $19.25 | 2024 | |
| Exeltis, USA INC. | $18.63 | 2021 | |
| Myovant Sciences INC. | $18.49 | 2022 | |
| Agile Therapeutics, INC. | $16.97 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Buxbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.